Free LIGHT Assay for Targeted ARDS and Crohn's Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with elevated free LIGHT levels, such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in COVID-19, lack effectiveness, and existing assays fail to accurately measure free LIGHT levels, which are crucial for understanding disease severity and potential treatment responses.
Innovation Solution
Development of a novel assay using the Simoa ™ ultra-high sensitive technology to detect and measure free LIGHT levels, employing a specific antibody pair to capture free LIGHT, and the use of anti-LIGHT antibodies to neutralize excessive free LIGHT levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to measure LIGHT levels, then the assay can be performed with current technology, but the measurement precision is insufficient to accurately detect free LIGHT levels
Solution Approach 1:
The assay separates bound LIGHT (complexed with DcR3) from free LIGHT through selective capture, allowing independent measurement of the active free LIGHT fraction. This segmentation enables accurate detection of the specific form of LIGHT that drives pathology, resolving the imprecision of measuring total LIGHT alone.
Solution Approach 2:
The patent introduces a capture antibody as an intermediary that selectively binds to free LIGHT, facilitating its isolation and detection. This intermediary molecule enables the assay to specifically target and measure free LIGHT levels with high precision, overcoming the limitations of existing non-specific assays.
2Reliability
If current treatments are used for ALI and ARDS, then standard care can be provided, but the treatments lack effectiveness in reducing disease severity
Solution Approach 1:
The patent extracts and targets the specific harmful agent (free LIGHT) that drives ALI and ARDS pathology. By isolating and neutralizing free LIGHT with anti-LIGHT antibodies, the treatment directly addresses the root cause of disease severity rather than providing non-specific supportive care, thereby improving treatment effectiveness.
Solution Approach 2:
The patent converts the harmful effect of excessive free LIGHT into a beneficial diagnostic and therapeutic target. By measuring and neutralizing free LIGHT, the treatment transforms the pathogenic cytokine into a controllable target, enabling precise intervention that reduces disease severity and improves patient outcomes.
3Ease of operation
If free LIGHT levels are not accurately measured, then treatment decisions cannot be optimized, but developing a new assay increases device complexity
Solution Approach 1:
The patent performs preliminary separation of free LIGHT from bound LIGHT through selective capture before measurement. This preliminary action simplifies the subsequent detection step by working with purified free LIGHT, making the assay easier to operate and interpret while enabling optimized treatment decisions based on accurate free LIGHT levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides accurate measurement of free LIGHT levels, enabling targeted therapy with anti-LIGHT antibodies, reducing disease severity and improving patient outcomes in conditions like COVID-19-associated ARDS and Crohn's Disease.
Implementation Method 1
employing a specific antibody pair to capture free LIGHT
Implementation Method 2
the use of anti-LIGHT antibodies to neutralize excessive free LIGHT levels
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.